Sushil Patel Sells 10,000 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Replimune Group Stock Performance

NASDAQ:REPL opened at $12.01 on Friday. The stock has a 50 day simple moving average of $12.23 and a 200 day simple moving average of $10.64. The stock has a market cap of $821.69 million, a P/E ratio of -3.94 and a beta of 1.26. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Research analysts anticipate that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. BMO Capital Markets raised their price objective on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Jefferies Financial Group lifted their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Roth Mkm assumed coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research report on Friday, November 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Replimune Group presently has an average rating of “Buy” and a consensus price target of $17.29.

Institutional Trading of Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its position in shares of Replimune Group by 12.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after purchasing an additional 52,498 shares in the last quarter. LMR Partners LLP boosted its stake in shares of Replimune Group by 145.8% in the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock valued at $904,000 after buying an additional 48,920 shares during the period. Millennium Management LLC grew its position in Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after buying an additional 2,656,173 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in Replimune Group by 282.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after acquiring an additional 53,313 shares during the period. Finally, Acadian Asset Management LLC increased its stake in Replimune Group by 63.2% during the 2nd quarter. Acadian Asset Management LLC now owns 185,516 shares of the company’s stock worth $1,668,000 after acquiring an additional 71,867 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.